<DOC>
	<DOCNO>NCT01083264</DOCNO>
	<brief_summary>Influence different application site blood level administration fertility control patch</brief_summary>
	<brief_title>Relative Bioavailability , Transdermally Administered EE GSD , 3 Applications Sites</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<criteria>Healthy female subject Age 1845 year Body mass index ( BMI ) 1830kg/mÂ² At least 3 month since delivery , abortion , lactation first screen examination Ability understand follow studyrelated instruction Willingness accept synchronize cycle use nonhormonal method contraception start synchronize cycle treatment period Contraindications use combine ( estrogen/progestin ) contraceptive ( e.g . history venous/arterial disease , liver disorder , migraine ) Skin diseases suspect alteration dermal resorption /or increase risk dermal intolerance Regular use medicine contraceptive Smokers ( age 31 45 year ) Clinically relevant finding ( e.g . blood pressure , physical gynecological examination , laboratory examination )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>